Research study for people with Type 1 Diabetes: EXALT
Currently recruiting
03/11/2017
Summary
The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes.
The investigational drug is a “therapeutic vaccine” and affects the body’s immune system response to a medical condition or disease. It is designed to stop the immune system from attacking cells that produce insulin, which may help insulin production in patients with recently diagnosed type 1 diabetes.
In this study, patients will receive 4 injections of the investigational drug over a period of 6 weeks. Total study participation will last approximately 24 weeks, which includes 8 study clinic visits for various tests and evaluations.
All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-related time and travel may be provided.
To pre-qualify for this study, you must:
- Be 18 to 30 years of age
- Have been diagnosed with type 1 diabetes in the last 6 months
- Have an insulin requirement
If you are interested in taking part please complete the Getting Involved form.
The Effect of Abatacept on the Immune System in Type 1 Diabetes
Recruitment Closed
Recruiting Site: Guy’s Hospital
09/08/2017
Summary
This study aims to gain a better understanding of the immune processes that lead to the destruction of insulin producing beta cells. Participants will be given the drug Abatacept for 6 months, in addition to their regular diabetes medication. They will have blood tests before, during and after treatment (6 visits in all) so that we can analyse their immune cells.
We are looking for male and female volunteers aged 18-45 who have been diagnosed with Type 1 Diabetes in the last 100 days.
If you are interested in taking part please complete the Getting Involved form.
Closed Loop from Onset in type 1 Diabetes
Recruiting sites:
- Cambridge University Hospitals NHS Foundation Trust
- Alder Hey Children’s NHS Foundation Trust
- Nottingham Children’s Hospital
- Oxford Children’s Hospital
- Southampton Childrens Hospital
- Royal Hospital for Sick Children, Edinburgh
Summary
CLOuD is a multicentre, randomised trial of an exciting new artificial pancreas device, in newly diagnosed adolescents with type 1 diabetes (T1D) funded by the EME Programme (an MRC and NIHR partnership) and the Helmsley Charitable Trust. The artificial pancreas is designed to mimic the normal healthy activity of beta-islet pancreatic cells in response to blood glucose levels. The device is a closed loop system combining real time continuous glucose monitoring with insulin pump therapy and a computer-based algorithm to calculate the amount of insulin required to keep blood glucose levels within target range. The aim is to prolong residual insulin secretion after T1D diagnosis, via intensive metabolic control using the artificial pancreas closed loop system, in order to minimise long-term complications and reduce the risk of hypoglycaemia. This is the first trial of its kind analysing the use of the artificial pancreas in newly diagnosed T1D patients.
96 participants aged 10 to 16 will be recruited within 10 working days of diagnosis of Type 1 Diabetes from 5 UK sites and will be randomised 1:1 to either closed loop or standard therapy (Multiple Daily Injections). Participants will have study visits and assessments every 3 months for a total of 24 months.
The Effect of Anti-IL-21 and Liraglutide in Newly Diagnosed Type 1 Diabetes
Recruitment Closed
Recruiting T1D UK Sites: Bristol, Birmingham, Cardiff, London QMUL, Newcastle, Sheffield, Swansea
Other participating sites: Belfast, Blackburn, London Imperial College, Plymouth Stevenage
Summary
This study will investigate if a new drug Anti-IL-21 when given together with another drug marketed for type 2 diabetes called liraglutide can preserve the beta cells in subjects diagnosed with type 1 diabetes.
The study is for adults aged 18-45 years who have been diagnosed with type 1 diabetes within 20 weeks of the screening visit.